Asia Pacific RNAi Therapeutics Market is expected to reach US$ 218.64 million in 2027

Published Date: 13 Oct 2020

Report : Asia Pacific RNAi Therapeutics Market Forecast to 2027 - COVID-19 Impact and Regional Analysis By Molecule Type (Small Interfering RNAs (siRNA) and MicroRNA (miRNA)), Application (Genetic Disorders, Oncology, Neurodegenerative Disorders, Cardiovascular, Respiratory Disorders, Infectious Diseases, Renal Diseases, and Others), Route of Administration (Intradermal Injections, Pulmonary Delivery, Intravenous Injections, Intraperitoneal Injections, and Others), and End User (Diagnostic Laboratories, Research and Academic Laboratories, and Hospitals) and Geography

Small Interfering RNAs (siRNA) Segment Held Largest Share of APAC RNAi TherapeuticsMarket in 2019


According to our new market research study on “Asia PacificRNAi Therapeutics Marketto 2027 – Regional Analysis and Forecast – by Molecule Type,Route of Administration, Application, and End User,”the Asia Pacific RNAi therapeutics market is expected to reach US$ 218.64 million by 2027 from US$ 107.63million in 2019, it is estimated to grow at a CAGR of 9.3% from 2020 to 2027. The report provides trends prevailing in the Asia PacificRNAi therapeutics market and the factors driving the market growth along with those hindering it.


In 2019, the small interfering RNAs (siRNA) segment accounted for higher share of the market. Growth of this segment is attributed to increasing preference for small interfering RNAs for drug development and growing number of research partnerships. ThemicroRNA (miRNA) segment is expected to register higher CAGR in the RNAi therapeutics market during the forecast period.


The growth of the Asia PacificRNAi therapeuticsmarketis mainly attributed togrowing prevalence of chronic conditions and rising investments for development of RNAi therapeutics. Additionally, increasing awareness about RNAi therapies and their benefits are anticipated to boost the research and innovations of RNAi therapeutics in the region,which would eventually drive the market growth.However,the high cost of RNAi therapy development is the major factor hindering the market growth in Asia Pacific.


Benitec Biopharma;Olix Pharmaceuticals, Inc;GlaxoSmithKline plc; Alnylam Pharmaceuticals, Inc; andArrowhead Pharmaceuticals, Incare among the leading companies operating in the Asia PacificRNAi therapeuticsmarket.


Asia Pacific RNAi Therapeutics Market, by Country, 2019 (%)

Asia Pacific RNAi Therapeutics Market, by Country, 2019 (%)


The report segments the Asia PacificRNAi therapeuticsmarket as follows:


Asia PacificRNAi TherapeuticsMarket– by MoleculeType

  • Small Interfering RNAs (siRNA)
  • MicroRNA (miRNA)


Asia PacificRNAi TherapeuticsMarket – by Route of Administration

  • Pulmonary Delivery
  • Intravenous Injections
  • Intradermal Injections
  • Intraperitoneal Injections
  • Others


Asia PacificRNAi TherapeuticsMarket – by Application

  • Oncology
  • Cardiovascular
  • Respiratory Disorders
  • Renal Diseases
  • Genetic Disorders
  • Neurodegenerative Disorders
  • Infectious Diseases
  • Others


Asia PacificRNAi Therapeutics Market – by End User

  • Research and Academic Laboratories
  • Hospitals
  • Diagnostic Laboratories


Asia PacificRNAi TherapeuticsMarket– by Country

  • Asia Pacific
    • Japan
    • China
    • India
    • South Korea
    • Australia


Contact Us

Contact Person: Sameer Joshi 

Phone: +1-646-491-9876

Email Id:

Download PDF Brochure